615TiP NIRVANA-1: A multicentre randomized study comparing carboplatin-paclitaxel (CP) followed by niraparib (nira) to CP–bevacizumab (bev) followed by nira-bev in patients with FIGO stage III ovarian high-grade epithelial cancer and no residual disease after upfront surgery
暂无分享,去创建一个
I. Ray-Coquard | E. Van Nieuwenhuysen | G. Freyer | J. Péron | F. Raspagliesi | M. Lim | A. González Martín | K. Hasegawa